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Objective. To conduct systematic analyses to evaluate the efficacy of progesterone therapy for the prevention of miscarriages in
pregnant women experiencing threatened abortion.Methods. In November 2016, we performed a systematic literature search and
identified 51 articles in PubMed, Embase, and Cochrane databases.We identified nine randomized trials that included 913 pregnant
women (including 322 treated with oral dydrogesterone, 213 treated with vaginal progesterone, and 378 control subjects) who met
the selection criteria. Results. The incidence of miscarriage was significantly lower in the total progesterone group than in the
control group (13.0% versus 21.7%; odds ratio, 0.53; 95% confidence interval (CI), 0.36 to 0.78; 𝑃 = 0.001; 𝐼2, 0%). Moreover,
the incidence of miscarriage was significantly lower in the oral dydrogesterone group than in the control group (11.7% versus
22.6%; odds ratio, 0.43; 95% CI, 0.26 to 0.71; 𝑃 = 0.001; 𝐼2, 0%) and was lower in the vaginal progesterone group than in the
control group, although this difference was nonsignificant (15.4% versus 20.3%; odds ratio, 0.72; 95% CI, 0.39 to 1.34; 𝑃 = 0.30;
𝐼2, 0%). However, the incidence of miscarriage was not different between the oral dydrogesterone and vaginal progesterone
groups. Conclusion. Progesterone therapy, especially oral dydrogesterone, can effectively prevent miscarriage in pregnant women
experiencing threatened abortion.
1. Introduction
Progesteronemaintains pregnancy by enhancing uterine qui-
escence [1]. During early pregnancy, the syncytiotrophoblast
secretes human chorionic gonadotropin (hCG), which stim-
ulates progesterone production in the corpus luteum by
preventing regression of this tissue [2]. After seven to nine
weeks of gestation, progesterone is directly secreted by the
syncytiotrophoblast [2, 3]. Low serum hCG or progesterone
levels may predict first trimester abortions [4]. During early
pregnancy in women with threatened abortion, progesterone
levels were lower in those who had a subsequent miscarriage
than in those whose pregnancies continued to fetal viability
[5]. Moreover, progesterone receptor antagonists may induce
abortion or labor by increasing myometrial contractility and
excitability throughout pregnancy [1, 6].
Threatened abortion, which occurs in 20% of all preg-
nancies, is diagnosed when vaginal bleeding with or without
abdominal pain occurs during the first half of pregnancy.The
required prerequisites for threatened abortion are a closed
cervix and an intrauterine viable fetus [7, 8]. Unfortunately,
nearly half of threatened abortions end in miscarriage [7, 8].
Progesterone has been used to treat threatened abortions, but
its efficacy remains unclear [8–17].
Previous meta-analyses have shown that progesterone
therapy may reduce the risk of miscarriage in pregnant
women with threatened abortion. However, these meta-
analyses were limited by a small number of included studies
[8, 9]. Furthermore, these systematic analyses only included
randomized studies that demonstrated the efficacy of the
oral progesterone dydrogesterone, a pure progestin that was
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developed in the 1950s [8, 9, 18], and revealed that vaginal
progesterone was ineffective [8, 9].
Although many studies have evaluated the impact of
progesterone as a treatment for threatened abortion, only a
few randomized studies have been conducted to explore this
issue. Recently, some additional randomized studies reported
the effect of progesterone therapy in pregnant women with
threatened abortion. In this study, using an updated sys-
tematic analysis, we aimed to evaluate the effectiveness of
progesterone therapy delivered via different administration
routes for preventing miscarriages in pregnant women with
threatened abortion.
2. Materials and Methods
2.1. Search Methods. In November 2016, we searched
PubMed, Embase, and Cochrane databases for all relevant
studies without limiting the publication year. A combination
of the following terms using Boolean operators was used to
perform the search: [(threatened abortion OR miscarriage)
AND (progesterone OR progestin) AND randomized trial]
and [(threatened abortion OR miscarriage) AND (dydro-
gesterone OR duphaston)]. Additional relevant studies that
were not identified by the database searches were identified
by examining the references of the selected clinical studies
and review articles.
2.2. Selection Criteria. The following inclusion criteria were
used for study selection: studies of pregnant women diag-
nosed with threatened abortion before 20 weeks of gestation,
studies that compared any type of progesterone therapy
with either placebo or conservative treatment, studies that
compared different administration routes of progesterone
therapy, studies that reported the incidence of miscarriage,
and randomized or quasi-randomized controlled studies.The
exclusion criteria were as follows: studies that were not case-
match controlled, noncomparative studies, studies not in
English, review articles, editorials, letters, case reports, in
vitro research studies, and studies using other therapeutic
agents. To avoid including duplicate information, when
multiple studies were found to have included overlapping
groups of patients, only the study with the largest number of
events was included in the meta-analysis. Some results were
published only in abstract form and not in full, and we found
that some clinically useful evidence could be extracted from
these studies.
2.3. Data Extraction and Outcomes of Interest. Two inves-
tigators developed a checklist for data recording, and they
independently extracted the data of interest from the studies.
If there was any disagreement between the findings of
these investigators, they were resolved by discussion. The
eligible population was classified into the following three
groups: patients administered oral dydrogesterone therapy,
patients administered vaginal progesterone therapy, and a
control group that was administered placebo or conservative
treatment.The following datawere retrieved from the studies:
the name of the first author, publication year, study design,
eligibility criteria, sample size, interventions, and incidence
ofmiscarriage.The incidence ofmiscarriagewas the principal
outcome of the meta-analysis and was compared among the
treatment groups.
2.4. Overall Quality of the Body of Evidence. Thequality of the
evidence for the principle outcomes was evaluated using the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) working group recommendations
[21] as follows: the limitation (e.g., risk of bias) of the included
studies, inconsistency of the observed effects, indirectness,
imprecision, and risk of publication bias. The quality of
the evidence was reported as follows: high quality, which
indicates that further research is highly unlikely to change the
confidence in the estimate of effect; moderate quality, which
indicates that further research is likely to have an important
impact on the confidence in the estimate of effect and may
change the estimate; low quality, which indicates that further
research is highly likely to have an important impact on the
confidence in the estimate of effect and is likely to change the
estimate; very low quality, which indicates that we are highly
uncertain about the estimate.
2.5. Publication Bias and Statistical Analyses. To analyze
the outcomes, a random-effects model was implemented
using the Mantel-Haenszel method. The heterogeneity of the
odds ratios (ORs) was assessed using the 𝐼2 statistic, and
publication bias was identified using funnel plots. To generate
a scatter plot, the horizontal axis was plotted as theORof each
study, and the vertical axis was plotted as the corresponding
standard error of the log of the OR. ReviewManager Version
5.3 software (The Nordic Cochrane Center, Copenhagen,
Denmark) was used for the meta-analysis. GRADE evidence
profiles were created using GRADEpro GDT. A 𝑃 value of
<0.05 indicated statistical significance. Subgroup analyses of
the risk ofmiscarriage according to eligibility criteria, vaginal
progesterone dose, and quality of studies were performed;
however, a subgroup analysis based on oral dydrogesterone
was not performed because similar doses were used in the
studies (Table 1).
3. Results
3.1. Search Results and Characteristics and Assessments of the
Risk of Bias in the Included Studies. Our literature search ini-
tially identified 51 potentially relevant studies; 8 randomized
controlled studies and 1 quasi-randomized study that met
the selection criteria were ultimately identified (Figure 1).
The characteristics of the included studies are provided in
Table 1, and assessments of the risk of bias in each study are
provided in Table 2. Alimohamadi et al. [11] andGerhard et al.
[13] did not include information regarding the type (natural
or synthetic) of vaginal progesterone that was administered.
The study by Hui et al. [20] was only published in abstract
form and did not provide information regarding the method
for confirming live embryos or the dosages and duration of
treatment with progestational agents. The included studies
had a total of 913 pregnant women (including 322 treatedwith
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Table 1: Characteristics of the included studies (𝑛 = 9).
Study Year Study design Eligibility criteria Samplesize Interventions
Alimohamadi
et al. [11]. 2013
Randomized
(double-blind)
Vaginal bleeding and uterine cramps
before the 20th week of pregnancy, live
singleton by ultrasound
71
71
Vaginal progesterone: 200mg, twice a day
for 1 week
Control: placebo using the same method
Czajkowski et
al. [19]. 2007
Randomized
(double-blind)
Vaginal bleeding usually accompanied
by abdominal pain before 12 weeks of
pregnancy, live singleton by ultrasound
29
24
Vaginal progesterone: micronized,
300mg, once per day for 6 weeksa
Oral dydrogesterone: 30mg using the
same method
El-Zibdeh
and Yousef
[12].
2009
Quasi-
randomized
(open-label)
Mild or moderate vaginal bleeding
during the first trimester of pregnancy,
live embryo by ultrasound
86
60
Oral dydrogesterone: 10mg, twice per day
until 1 week after bleeding had stopped
Control: conservative treatment
Gerhard et al.
[13]. 1987
Randomized
(double-blind)
Vaginal bleeding during the first
trimester of pregnancy, live singleton
by ultrasound
17
17
Vaginal progesterone: 25mg, twice per day
for 14 days after bleeding had stopped
Control: placebo using the same method
Hui et al.
[20].b 2015 Randomized
Vaginal bleeding between weeks 6 and
10 of pregnancy
41
42
Vaginal progesterone: micronized
Oral dydrogesterone
Omar et al.
[14]. 2005
Randomized
(open-label)
Mild or moderate vaginal bleeding
before 13 weeks of pregnancy, live
embryo by ultrasound
74
80
Oral dydrogesterone: initial: 40mg;
maintenance: 10mg, twice per day until
bleeding had stopped or for 1 weekc
Control: conservative treatment
Pandian [15]. 2009 Randomized(open-label)
Vaginal bleeding up to the 16th week of
pregnancy, live embryo by ultrasound
96
95
Oral dydrogesterone: initial: 40mg;
maintenance: 10mg, twice per day until
the 16th week of pregnancy
Control: conservative treatment
Palagiano et
al. [16]. 2004
Randomized
(double-blind)
Vaginal bleeding and uterine cramps
between weeks 6 and 12 of pregnancy
with a previous diagnosis of
inadequate luteal phase, live embryo
by ultrasound
25
25
Vaginal progesterone: micronized, 90mg,
once per day for 5 daysd
Control: placebo using the same method
Yassaee et al.
[17]. 2014
Randomized
(single-blind)
Vaginal bleeding until the 20th week of
pregnancy, live singleton by ultrasound
30
30
Vaginal progesterone: micronized,
400mg, once per day until bleeding
stopped within less than 1 week
Control: conservative treatmente
aAdamed Inc., Poland; blimited information was available because the study was published only in abstract form; cunclear data regarding the duration of
treatment; dCrinone 8% (progesterone gel, Merck Serono Inc., Germany); eCyclogest (Actavis Inc., UK).
oral dydrogesterone, 213 treated with vaginal progesterone,
and 378 control subjects) (Tables 1 and 3; Figure 2).
3.2. Risk of Miscarriage Based on the Route of Progesterone
Administration in Pregnant Women Experiencing Threatened
Abortion. The incidence of miscarriage was significantly
lower in the total progesterone group than in the control
group (13.0% versus 21.7%; odds ratio, 0.53; 95% confidence
interval (CI), 0.36 to 0.78; 𝑃 = 0.001; 𝐼2, 0%; 7 RCTs,
777 pregnant women; low quality evidence; Table 3(a),
Figure 2(a), and Supplementary Figure 1(a)). Moreover, the
incidence of miscarriage was significantly lower in the oral
dydrogesterone group than in the control group (11.7% versus
22.6%; odds ratio, 0.43; 95% CI, 0.26 to 0.71; 𝑃 = 0.001;
𝐼2, 0%; 3 RCTs, 491 pregnant women; low quality evidence;
Table 3(a), Figure 2(b), and Supplementary Figure 1(b)) and
was lower in the vaginal progesterone group than in the
control group; however, this difference was not significant
(15.4% versus 20.3%; odds ratio, 0.72; 95% CI, 0.39 to 1.34;
𝑃 = 0.30; 𝐼2, 0%; 4 RCTs, 286 pregnant women; high quality
evidence; Table 3(a), Figure 2(c), and Supplementary Figure
1(c)). However, the incidence of miscarriage was not different
between the oral dydrogesterone and vaginal progesterone
groups (17.1% versus 16.7%; odds ratio, 1.06; 95% CI, 0.42 to
2.66; 𝑃 = 0.90; 𝐼2, 0%; 2 RCTs, 136 pregnant women; low
quality evidence; Table 3(b), Figure 2(d), and Supplementary
Figure 1(d)).
3.3. Subgroup Analyses. When comparing the subgroups
based on eligibility criteria, the incidence of miscarriage
among patients experiencing threatened abortion within 12
completed weeks of gestation was significantly lower in the
total progesterone group than in the control group (𝑃 =
0.01). In patients experiencing threatened abortion before
20 weeks of gestation, the incidence of miscarriage was also
lower in the total progesterone group than in the control
group, although this difference was not significant (𝑃 =
0.20). When comparing the subgroups according to the
vaginal progesterone dose (400mg or less than 400mg)
because of the large discrepancy between the doses, high
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Table 4: Subgroup analyses of risk of miscarriage according to eligibility criteria and vaginal progesterone dose.
Subgroups Studies, 𝑛 Number of patients (%) OR (95% CI) 𝑃 value Heterogeneity (𝐼2)
Progesterone Control
Eligibility criteria
Threatened abortion within 12
completed weeks of gestation 4 (12, 13, 14, 16) 22/202 (10.9) 35/182 (19.2) 0.47 (0.26–0.86) 0.01 0%
Threatened abortion before 20
weeks of gestation 3 (11, 15, 17) 30/197 (15.2) 47/196 (24.0) 0.60 (0.27–1.31) 0.20 53%
Vaginal progesterone dose
Higha 2 (11, 17) 18/101 (17.8) 20/101 (19.8) 0.85 (0.35–2.05) 0.72 30%
Lowb 2 (13, 16) 4/42 (9.5) 9/42 (21.4) 0.39 (0.11–1.37) 0.14 0%
aHigh-dose use of vaginal progesterone included studies that administered 400mg per day for 1 week or until bleeding stopped within less than 1 week. bLow-
dose use of vaginal progesterone included studies using a dose lower than the reported high dose.
51 potentially relevant studies identied 
from database searches
16 studies retrieved for full-text
evaluation
9 studies included in the meta-analysis
(8 randomized studies and 1 quasi-
randomized study) 
35 studies excluded upon abstract
because they were non-case matched,
noncomparative, non-English studies, review 
articles, letters, in vitro studies, and studies 
using other therapeutic agents
3 studies excluded because they were neither 
randomized nor quasi-randomized 
controlled trials
13 studies retrieved for more detailed 
evaluation
4 studies excluded because they had 
inadequate data for extraction
Figure 1: Flow chart of the procedure used for study selection.
doses of progesterone were not associated with the incidence
of miscarriage between the groups (𝑃 = 0.72). However,
among the groups treated with a lower dose of hormone, the
incidence of miscarriage was lower in the progesterone group
than in the control group, although this difference was not
significant (𝑃 = 0.14; Table 4 and Supplementary Figure 2).
4. Discussion
In this meta-analysis, we demonstrated that progesterone
therapy may be effective in preventing miscarriages in preg-
nant women with threatened abortion. In particular, oral
dydrogesterone prevented miscarriage in pregnant women
more effectively than the control-treated groups (placebo or
conservative treatment), although there was no difference
between oral and vaginal progestational agents in preventing
miscarriages in pregnant women experiencing threatened
abortion.
The route of administration may influence the efficacy
of progesterone therapy during pregnancy [22, 23]. Vaginal
progesterone administration resulted in higher endometrial
progesterone concentrations than those observed in patients
administered oral and intramuscular progesterone [23]. Oral
and vaginal administration routes are noninvasive, whereas
intramuscular administration is invasive. Additionally, the
oral and vaginal routes of administration are associated with
acceptable and minimal side effects, respectively, whereas
side effects were reported in one-third of pregnant women
who received weekly intramuscular injections of proges-
terone to prevent recurrent preterm delivery [22–24]. Oral
synthetic progestational agents, including dydrogesterone,
have been developed to eliminate issues related to the variable
bioavailability of natural formulations of oral progesterone
[23]. A randomized study reported that micronized vaginal
progesterone, but not oral dydrogesterone, decreased spiral
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Figure 2: Forest plots and risk of bias: risk of miscarriage in pregnant women experiencing threatened abortion based on the route of
progesterone administration. (a) Total progesterone versus control treatments. (b) Oral dydrogesterone versus control treatments. (c) Vaginal
progesterone versus control treatments. (d) Oral dydrogesterone versus vaginal progesterone treatments. The risk of bias for each metric was
assessed as low (+), high (−), or unclear (blank) for all the included studies as follows: A, random sequence generation (selection bias);
B, allocation concealment (selection bias); C, blinding of the participants and personnel (performance bias); D, blinding of the outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. M-H, Mantel-
Haenszel; CI, confidence interval.
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artery pulsatility and the resistance index in the uteroplacen-
tal circulation of early pregnancies with threatened abortion
[19].
In previousmeta-analyses that included only randomized
studies, vaginal and intramuscular progesterone administra-
tion effectively reduced the risk of preterm birth without
any deleterious effects on fetal development [25, 26]. In a
randomized study, a lower risk of preterm birth was asso-
ciated with oral micronized progesterone than placebo [27].
Additionally, in a recent meta-analysis, oral dydrogesterone
was as effective as vaginal progesterone for luteal phase sup-
port in assisted reproduction [28]. It has also been reported
that intramuscular progesterone administration is associated
with implantation, clinical pregnancy, and delivery rates that
are comparable to those resulting from treatment with vagi-
nal progesterone during stimulated IVF cycles [29]. These
previous studies demonstrated that various progestational
agents may induce similar outcomes despite the fact that
differences in their efficacy were associated with the route of
administration. In support of these studies, ourmeta-analysis
showed that therewas no difference in the rate ofmiscarriages
between pregnantwomenwith threatened abortionwhowere
administered oral or vaginal progestational agents, although
the small numbers of pregnant women and studies that were
included limit the significance of these results.
Many studies have supported the efficacy of vaginal
progesterone for preventing preterm births and luteal phase
defects [25, 26, 28, 29]. Therefore, it is possible that miscar-
riages in pregnant women with threatened abortion might
also be prevented by vaginal progesterone. However, a
previous meta-analysis that included a small number of
randomized studies showed that oral dydrogesterone, but not
vaginal progesterone, reduced the incidence of miscarriage
in pregnant women with threatened abortion [9]. Although
we included a few additional recently reported randomized
studies in our meta-analysis, the number of studies analyzed
remained small. Our study also failed to show that vaginal
progesterone was more effective in preventing miscarriages
in pregnant women with threatened abortion than that in the
controls, although we did find that oral dydrogesterone was
effective. However, based on the subgroup analyses, our study
showed that progesterone therapy was effective in preventing
miscarriage—especially in pregnant women experiencing
threatened abortion during the first trimester of pregnancy.
This meta-analysis clearly showed the effectiveness of pro-
gesterone therapy for the prevention of miscarriage. These
findings indicate that well-designed and large-scale studies
are necessary to further demonstrate impact of progesterone
therapy.
Our meta-analysis had several limitations. First, only
studies that were either randomized or quasi-randomized
and evaluated either oral dydrogesterone or vaginal pro-
gesterone administration were included in this analysis.
Unfortunately, there were neither randomized nor quasi-
randomized trials that evaluated the efficacy of intramus-
cular progesterone administration or oral formulations of
progestins other than dydrogesterone in pregnant women
experiencing threatened abortion. Second, because there is a
paucity of studies that provided adequate data, we included
small-scale studies as well as those with poor methodological
quality in our analysis. Third, in the analyses comparing
efficacy between oral progesterone and control treatments,
between vaginal progesterone and control treatments, and
between oral and vaginal progesterone, only a few eligible
studies that included a small cohort of pregnant women
could be analyzed. Finally, our searches were limited to
the studies published in English. We found 2 studies not
written in English that met our eligibility criteria. However,
the significance of those studies was limited based on the
publication year (1967) and lack of accessibility (no available
abstract in English and difficulty finding experts in the
relevant languages).
In conclusion, based on our systematic review and meta-
analysis, we suggest that progesterone therapy, especially
oral dydrogesterone, may effectively prevent miscarriages in
pregnant women with threatened abortion. Although the
number, scale, and methodological quality of the eligible
studies limit the significance of our meta-analysis results,
these results are important because we systemically ana-
lyzed all currently available randomized studies. Large-scale,
multicenter, randomized and controlled studies are needed
to better evaluate the efficacy of progesterone therapy in
pregnant women with threatened abortion.
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